Biosion enters research collaboration with ImmunoGen to create novel antibody drug conjugates

Biosion USA, Inc. (Biosion), a global R&D biotechnology company, announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen, Inc., a leader in developing next generation ADCs. In the joint research effort, Biosion will leverage its proprietary SynTracer high-throughput (HT) endocytosis platform to generate highly selective antibodies to targets allocated by each company and ImmunoGen will provide their proprietary linker-payload technology to create novel ADCs. "We are excited about our new joint research effort with ImmunoGen, a world-renowned leader in ADCs," said Hugh Davis, Ph.D., chief operating officer, and president of Biosion USA, Inc. "This collaboration will take advantage of the strengths of each company; ImmunoGen

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!